Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8684MR)

This product GTTS-WQ8684MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8684MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6840MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ9204MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ12512MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ4043MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ15772MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ15285MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ5492MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ4332MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW